ReviewMediators of inflammation2017
The Intricate Link among Gut "Immunological Niche," Microbiota, and Xenobiotics in Intestinal Pathology.
Review in Mediators of inflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- The microbiota at the interface of environmental toxicants and the brain.Cell metabolism · 2026Review
- Rifaximin's therapeutic spectrum: approved indications and experimental insights into emerging uses.Pharmacological reports : PR · 2026Review
- Bacteroides thetaiotaomicron: A symbiotic ally against diarrhea along with modulation of gut microbial ecological networks via tryptophan metabolism and AHR-Nrf2 signaling.Journal of advanced research · 2026Article
- Neuroimmune Crossroads: Pathophysiological Links Between Bipolar Disorder and Inflammatory Bowel Disease.Actas espanolas de psiquiatria · 2025Review
- Gut microbiome and nutritional strategies in gastrointestinal cancers: Clinical implications and therapeutic perspectives.World journal of clinical oncology · 2025Review
- Brain Structures, Circuits, and Networks Involved in Immune Regulation, Periodontal Health, and Disease.Life (Basel, Switzerland) · 2025Review
- Andrographolide derivative CX-10 alleviates ulcerative colitis by modulating autophagy and cellular stress.Journal of clinical biochemistry and nutrition · 2025Article
- Human anaerobic microbiome: a promising and innovative tool in cancer prevention and treatment by targeting pyruvate metabolism.Cancer immunology, immunotherapy : CII · 2023Review
- Gut Microbiota, Inflammatory Bowel Disease, and Cancer: The Role of Guardians of Innate Immunity.Cells · 2023Review
- Microbial gut dysbiosis induced by xenobiotics in model organisms and the relevance of experimental criteria: a minireview.Gut microbiome (Cambridge, England) · 2023Review
- Exploring the gut microbiota: lifestyle choices, disease associations, and personal genomics.Frontiers in nutrition · 2023Review
- The interplay betweenFrontiers in cellular and infection microbiology · 2022Review
- Probing gut-brain links in Alzheimer's disease with rifaximin.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19.Microorganisms · 2021Article
- RepresentativeInternational journal of molecular sciences · 2021Article
- Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model.Journal of personalized medicine · 2021Article
- Chemical profiling of root bark extract fromPeerJ · 2021Article
- Influence of microbiota on immunity and immunotherapy for gastric and esophageal cancers.Gastroenterology report · 2020Review
- The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer.International journal of molecular sciences · 2019Review
- Therapeutic Effect ofFrontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBDs) are diseases characterized by various degrees of inflammation involving the gastrointestinal tract. Ulcerative colitis and Crohn's disease are characterized by a dysregulated immune response leading to structural gut alterations in genetically predisposed individuals. Diverticular disease is characterized by abnormal immune response to normal gut microbiota. IBDs are linked to a lack of physiological tolerance of the mucosal immune system to resident gut microbiota and pathogens. The disruption of immune tolerance involves inflammatory pathways characterized by an unbalance between the anti-inflammatory regulatory T cells and the proinflammatory Th1/Th17 cells. The interaction among T cell subpopulations and their related cytokines, mediators of inflammation, gut microbiota, and the intestinal mucosa constitute the gut "immunological niche." Several evidences have shown that xenobiotics, such as rifaximin, can positively modulate the inflammatory pathways at the site of gut immunological niche, acting as anti-inflammatory agents. Xenobiotics may interfere with components of the immunological niche, leading to activation of anti-inflammatory pathways and inhibition of several mediators of inflammation. In summary, xenobiotics may reduce disease-related gut mucosal alterations and clinical symptoms. Studying the complex interplay between gut immunological niche and xenobiotics will certainly open new horizons in the knowledge and therapy of intestinal pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.